LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

杜瓦卢马布 阶段(地层学) 放化疗 医学 肿瘤科 内科学 总体生存率 癌症 地质学 古生物学 免疫疗法 无容量
作者
Jeffrey D. Bradley,Shunichi Sugawara,K.H. Lee,Gyula Ostoros,Ahmet Demirkazık,Milada Zemanová,Virote Sriuranpong,Ana Caroline Zimmer Gelatti,J. Menezes,Bogdan Żurawski,Michael Newton,P. Chander,Nan Jia,Zofia F. Bielecka,Mustafa Özgüroĝlu
出处
期刊:ESMO open [Elsevier BV]
卷期号:9: 102986-102986 被引量:23
标识
DOI:10.1016/j.esmoop.2024.102986
摘要

The PACIFIC trial established consolidation durvalumab (D) after chemoradiotherapy (CRT) as SoC for pts with unresectable stage III NSCLC. However, up to 30% of pts are ineligible due to progression during/shortly after CRT or inadequate recovery from CRT-related toxicity. The phase III PACIFIC-2 trial evaluated D initiated concurrently with platinum-based concurrent CRT (cCRT) followed by consolidation D, compared with cCRT alone, in pts with unresectable stage III NSCLC. PACIFIC-2 (NCT03519971) was a randomized double-blind study. Treatment (Tx)-naïve pts with WHO PS 0/1 and histologically/cytologically confirmed stage III NSCLC were randomized (2:1) to receive SoC cCRT concurrently with D or placebo (PBO) IV Q4W, stratified by age and disease stage. Pts then received consolidation D/PBO until progression, unacceptable toxicity, consent withdrawal, or other discontinuation criteria. The primary endpoint was PFS (BICR; RECIST v1.1). 327/328 randomized pts received Tx (D arm, n=219; PBO arm, n=108). A higher % of pts in the D vs PBO arm had T4 tumors (57.5% vs 48.6%) and squamous histology (55.3% vs 47.7%). As of 7 Sep 2023 (data cutoff), median follow-up in all (censored) pts was 30.5 (55.5) months. There was a trend (not statistically significant) toward improved PFS with D vs PBO (HR, 0.85; 95% CI: 0.65–1.12; P=0.247); median PFS was 13.8 vs 9.4 months. There was no significant difference in OS (HR, 1.03; 95% CI: 0.78–1.39; P=0.823); median OS was 36.4 vs 29.5 months. Max grade 3/4 any-cause AEs occurred in 53.4% vs 59.3% with D vs PBO; 25.6% vs 12.0% had AEs that led to discontinuation of D/PBO (14.2% vs 5.6% in the first 4 months); 47.0% vs 51.9% had serious AEs; and 13.7% vs 10.2% had AEs with outcome of death. Pneumonitis/radiation pneumonitis occurred in 28.8% vs 28.7%. In PACIFIC-2, concurrent D and CRT did not improve outcomes vs CRT alone. Overall, safety and tolerability were consistent with the known profiles for D and CRT, although one quarter of pts had AEs leading to discontinuation of D, the majority of which occurred in the first 4 months. Consolidation D remains SoC for pts with unresectable stage III NSCLC who do not progress on definitive CRT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dorkoom发布了新的文献求助10
刚刚
远航完成签到,获得积分10
刚刚
2秒前
2秒前
trevor发布了新的文献求助10
3秒前
李治稳发布了新的文献求助10
3秒前
Jasper应助000采纳,获得10
5秒前
Hello应助老迟到的沛萍采纳,获得10
5秒前
Holly12345应助内向寒云采纳,获得10
6秒前
yyy完成签到,获得积分10
7秒前
cbx完成签到,获得积分10
9秒前
打打应助九卫采纳,获得10
9秒前
令宏发布了新的文献求助10
9秒前
香蕉觅云应助ning采纳,获得10
10秒前
三年三班三井寿完成签到,获得积分10
10秒前
天天快乐应助shinn采纳,获得10
11秒前
岛不言完成签到,获得积分10
12秒前
NexusExplorer应助学者宫Sir采纳,获得10
13秒前
14秒前
成功i吃u官方完成签到,获得积分20
15秒前
情怀应助H7采纳,获得10
16秒前
ziyue驳回了大个应助
16秒前
干净的白曼完成签到 ,获得积分10
17秒前
000发布了新的文献求助10
17秒前
18秒前
ComVivas发布了新的文献求助10
19秒前
19秒前
19秒前
20秒前
21秒前
21秒前
21秒前
彩色垣发布了新的文献求助10
22秒前
在水一方应助幼汁汁鬼鬼采纳,获得20
22秒前
23秒前
大大小小发布了新的文献求助10
24秒前
25秒前
lilian发布了新的文献求助10
25秒前
H7完成签到,获得积分10
26秒前
liaomr发布了新的文献求助10
26秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975339
求助须知:如何正确求助?哪些是违规求助? 3519670
关于积分的说明 11199199
捐赠科研通 3256002
什么是DOI,文献DOI怎么找? 1798043
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305